Total Funding
53
55
Total FundingPost-IPO Equity raised
Growth Score
-4 pts
Heat Score
7 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
80916
Bio-Path Holdings is a biotechnology company developing therapeutic products for the liposomal delivery of nucleic acids in cancer patients.
- Ana Tari Ashizawa: Co-Founder , SVP of Research, Development & Clinical Design
Douglas P. Morris: Co-Founder & Director of Investor Relations
About the Company
Bio-Path is a biotechnology company developing DNAbilize, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous infusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers and prexigebersen-A, a drug
product modification of prexigebersen, is under consideration by the FDA to commence Phase 1 studies in solid tumors.
Women Founded
